"Tetrabenazine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A drug formerly used as an antipsychotic and treatment of various movement disorders. Tetrabenazine blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system.
| Descriptor ID |
D013747
|
| MeSH Number(s) |
D03.633.100.834.850
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tetrabenazine".
Below are MeSH descriptors whose meaning is more specific than "Tetrabenazine".
This graph shows the total number of publications written about "Tetrabenazine" by people in this website by year, and whether "Tetrabenazine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 2 | 0 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tetrabenazine" by people in Profiles.
-
Real-world experience with VMAT2 inhibitors in Tourette syndrome. J Neurol. 2023 Sep; 270(9):4518-4522.
-
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021 10 01; 4(10):e2128204.
-
Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021 10 01; 4(10):e2129397.
-
Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism Relat Disord. 2020 08; 77:141-145.
-
Treatment of Tardive Dyskinesia. Neurol Clin. 2020 05; 38(2):379-396.
-
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019 12; 90(12):1317-1323.
-
Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol. 2019 Mar/Apr; 42(2):37-41.
-
Deutetrabenazine in the treatment of tardive dyskinesia. Neurodegener Dis Manag. 2019 04; 9(2):59-71.
-
VMAT2 Inhibitors in Neuropsychiatric Disorders. CNS Drugs. 2018 12; 32(12):1131-1144.
-
Deutetrabenazine for the treatment of Huntington's chorea. Expert Rev Neurother. 2018 08; 18(8):625-631.